• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    12/31/20 4:05:00 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XERS alert in real time by email

    CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on December 30, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 38,250 shares, and restricted stock units for an aggregate of 35,100 shares, of its common stock to 7 new employee(s) under Xeris’ Inducement Equity Plan.

    Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock options will vest over a period of four years, either 25% on the first anniversary of the grant with the remaining 75% vesting in thirty-six equal monthly installments thereafter, or 36% on 18 months after the grant date with the remaining 64% vesting in ten equal quarterly installments thereafter, and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. The restricted stock units will vest over a period of four years in equal annual installments, and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.

    About Xeris Pharmaceuticals, Inc.

    Xeris (NASDAQ: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

    With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

    Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

    Get the next $XERS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XERS

    DatePrice TargetRatingAnalyst
    11/11/2024$3.00Overweight → Neutral
    Piper Sandler
    3/28/2024$5.00Outperform
    Oppenheimer
    8/28/2023$4.50Buy
    Craig Hallum
    10/21/2022$4.00Buy
    Jefferies
    4/28/2022$6.50Buy
    Craig Hallum
    2/16/2022$8.00 → $6.00Outperform
    SVB Leerink
    12/31/2021$6.00 → $8.00Outperform
    SVB Leerink
    12/31/2021$4.25 → $5.40Buy
    HC Wainwright & Co.
    More analyst ratings

    $XERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 5:17:37 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Xeris Biopharma Holdings Inc. (Amendment)

      SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 4:34:36 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      1/26/24 4:23:46 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Financials

    Live finance-specific insights

    See more
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

      Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today annou

      3/6/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Xeris Biopharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00

      11/11/24 7:52:12 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Xeris Biopharma with a new price target

      Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00

      3/28/24 7:52:34 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Xeris Biopharma with a new price target

      Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.50

      8/28/23 7:53:14 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Xeris Biopharma Holdings Inc.

      EFFECT - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/14/25 12:15:23 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Xeris Biopharma Holdings Inc.

      10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/8/25 4:12:34 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/8/25 7:22:16 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $XERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $XERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Director Schmid John P. bought $10,147 worth of shares (4,515 units at $2.25) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/13/24 4:15:08 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. bought $10,134 worth of shares (4,285 units at $2.37) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/12/24 6:28:50 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schmid John P. bought $10,314 worth of shares (5,400 units at $1.91) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      5/10/24 4:04:26 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Announces Details for Analyst & Investor Day

      Hybrid Event Offering In-Person or Virtual Attendance on Tuesday, June 3, 2025 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for its first in-person and virtual analyst and investor day in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EST. The event will feature key opinion leaders (KOLs) Antonio C. Bianco, MD, PhD (University of Texas Medical Branch), Francesco S. Celi, MD, MHSc (UConn Health), and Eliza B. Geer, MD (Memorial Sloan Kettering Cancer Center), who will join company management to di

      5/20/25 7:30:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

      Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X

      2/24/25 8:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Announces CEO Succession Plan

      John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20

      7/8/24 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Mcculloch Kevin covered exercise/tax liability with 733 shares, decreasing direct ownership by 0.04% to 1,683,585 units (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      4/3/25 4:20:05 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brady James Aloysius was granted 100,000 shares (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      3/28/25 4:45:00 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Brady James Aloysius

      3 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      3/28/25 4:44:04 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care